10-Q: Kraig Biocraft Laboratories Reports Q1 2025 Results: Losses Continue Amid Efforts to Secure Funding

Kraig Biocraft Laboratories reports ongoing losses in Q1 2025, emphasizing the need for additional capital to sustain operations and execute its business plan.

Summary

• Kraig Biocraft Laboratories reported a net loss of $600,033 for the three months ended March 31, 2025, compared to a net loss of $507,875 for the same period in 2024.
• The company's operating expenses totaled $580,492, an increase from $448,710 in the prior year.
• Revenue remained at $0 for both periods.
• As of March 31, 2025, the company had a working capital deficit of $9,373,405 and a stockholders' deficit of $8,547,798.
• Cash and cash equivalents were reported at $397,001 as of March 31, 2025, down from $673,264 at the end of 2024.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan.
• The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., potentially allowing the company to sell up to $10 million of its shares of common stock.
• During the three months ended March 31, 2025, the Company sold 2,213,333 shares of common stock for total cash proceeds of $168,236.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the ongoing losses, working capital deficit, and the auditor's doubt about the company's ability to continue as a going concern. The potential for a capital raise through the SEPA provides a glimmer of hope, but the overall outlook is concerning.

Positives

• The company has a Standby Equity Purchase Agreement (SEPA) in place, providing a potential source of funding up to $10 million.
• The company is actively pursuing collaborative research and product testing opportunities.
• The company is actively pursuing an uplist to a national exchange if such an opportunity presents itself.

Negatives

• The company reported a net loss of $600,033 for the three months ended March 31, 2025.
• The company has a significant working capital deficit of $9,373,405.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company's cash reserves are low, with only $397,001 on hand as of March 31, 2025.
• The company has not previously demonstrated that it will be able to expand its business through an increased investment in its research and development efforts.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's research and development efforts may not be successful.
• The company's products may face rejection in the marketplace.
• The company may be unable to obtain sufficient financing on satisfactory terms.
• The company faces risks inherent in growing an enterprise, including limited capital resources.
• The company's disclosure controls and procedures were not effective as of March 31, 2025.

Future Outlook

The company plans to accelerate and expand commercial scale production of its recombinant spider silk, expand research and development, create a line of recombinant spider silk fashion wear, continue the expansion of its overseas production operations, accelerate its microbiology research and development to create more advanced materials, develop more advanced spider silk and non-spider silk based fibers for select target markets, consider buying an established revenue producing company in a compatible business, actively consider pursuing collaborative research opportunities with private laboratories, actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile, and other industries, actively pursue additional collaborative commercialization, marketing, and manufacturing opportunities with companies in the textile and material sectors for the fibers it developed and for any new polymers that it creates in 2025 and going forward, and actively pursue an uplist to a national exchange if such an opportunity presents itself.

Management Comments

• Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

Industry Context

The company operates in the specialty fiber and technical textile industries, seeking to introduce innovative materials with superior properties compared to existing materials.

Comparison to Industry Standards

• It is difficult to compare Kraig Biocraft Laboratories to industry standards due to its unique focus on recombinant spider silk production.
• Comparisons could be made to companies in the specialty fiber market, such as DuPont or Teijin, but these companies have a much broader product portfolio and established revenue streams.
• The company's success depends on its ability to scale production and commercialize its technology, which is a challenge faced by many biotechnology companies.

Related Party Transactions

• The company has significant related party transactions, including loans from its CEO and accrued expenses and interest payable to related parties.
• As of March 31, 2025, the Company owed $7,578,833 to its related parties in accrued salaries and accrued interest.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial condition and the potential for dilution from future equity offerings.
• Employees face uncertainty due to the company's going concern status.
• The company's ability to fulfill its obligations to suppliers and creditors is uncertain.

Next Steps

• The company plans to accelerate and expand commercial scale production of its recombinant spider silk.
• The company plans to expand its research and development to accelerate its work in creating next generation materials and to improve the robustness of its recombinant spider silk lines.
• The company plans to create a line of recombinant spider silk fashion wear either under its own brand name or in partnership with existing commercial entities.
• The company plans to continue the expansion of its overseas production operations, including working with local contractors or cooperatives and the hiring of additional direct staff, as needed.
• The company plans to accelerate its microbiology research and development to create more advanced materials.
• The company plans to develop more advanced spider silk and non-spider silk based fibers for select target markets.
• The company will consider buying an established revenue producing company in a compatible business, in order to broaden its financial base and facilitate the commercialization of its products.
• The company will also actively consider pursuing collaborative research opportunities with private laboratories in areas of research which overlap the company's existing research and development.
• The company plans to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile, and other industries.
• The company plans to actively pursue additional collaborative commercialization, marketing, and manufacturing opportunities with companies in the textile and material sectors for the fibers it developed and for any new polymers that it creates in 2025 and going forward.
• The company plans to actively pursue an uplist to a national exchange if such an opportunity presents itself.

Key Dates

Keywords

Kraig Biocraft Laboratories, spider silk, recombinant DNA, financial results, going concern, SEPA, loss, capital, silkworms, textile